IsoDGR‐Tagged Albumin: A New αvβ3 Selective Carrier for Nanodrug Delivery to Tumors
- 12 November 2012
- Vol. 9 (5), 673-678
- https://doi.org/10.1002/smll.201202310
Abstract
A new cyclic peptide containing the isoDGR motif that, after coupling to albumin, selectively binds αvβ3, an integrin overexpressed in the tumor vasculature. IsoDGR-tagged albumin binds tumor vessels and can be exploited as a carrier for the preparation of tumor vasculature-selective nanomedicines, such as gold nanoparticles (Au) carrying tumor necrosis factor α (TNF), a potent vascular damaging agent.Keywords
This publication has 22 references indexed in Scilit:
- Impact of albumin on drug delivery — New applications on the horizonJournal of Controlled Release, 2012
- Isoaspartate-dependent molecular switches for integrin–ligand recognitionJournal of Cell Science, 2011
- Critical Role of Flanking Residues in NGR-to-isoDGR Transition and CD13/Integrin Receptor SwitchingOnline Journal of Public Health Informatics, 2010
- IntegrinsCell and tissue research, 2009
- Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticlesJournal of Controlled Release, 2008
- The neovasculature homing motif NGR: more than meets the eyeBlood, 2008
- Integrins in angiogenesis and lymphangiogenesisNature Reviews Cancer, 2008
- β8 Integrin Binds Rho GDP Dissociation Inhibitor-1 and Activates Rac1 to Inhibit Mesangial Cell Myofibroblast DifferentiationOnline Journal of Public Health Informatics, 2006
- αVβ8 integrin is a Schwann cell receptor for fibrinExperimental Cell Research, 2003
- N-Methylated Cyclic RGD Peptides as Highly Active and Selective αVβ3Integrin AntagonistsJournal of Medicinal Chemistry, 1999